...Bristol-Myers Squibb Co. (NYSE:BMY) is tapping Sirenas LLC’s AI platform Atlantis to discover microbiome metabolites for...
...organisms, such as sponges, cyanobacteria and algae. Chairman and Head of Innovation Eduardo Esquenazi said Sirenas...
...“Life in the ocean has been evolving so much longer than anywhere else.” Jake Beverage, Sirenas...

...as a predictor of efficacy for cancer immunotherapies Small molecules against microbiome targets; microbiome-based diagnostics Sirenas...
...Squibb Co. (NYSE:BMY) Discovering drugs against undisclosed targets using Atlantis data mining technology to search Sirenas'...

...Sirenas LLC (San Diego, Calif.) and Bristol-Myers Squibb Co. (NYSE:BMY) partnered to use Sirenas' ATLANTIS drug...
...biotech would be eligible for additional milestones and royalties. Sirenas declined to disclose specific indications. Sirenas...
...declined to disclose specific indications. Sirenas CEO and Co-founder Jake Beverage told BioCentury the first Sirenas-derived...

...partnered to discover and develop small molecules in oncology, neurology, regenerative medicine and neglected diseases. Sirenas...
...will co-develop compounds through early clinical trials. The institute declined to disclose financial terms, and Sirenas...
...not respond in time for publication. California Institute for Biomedical Research , La Jolla, Calif. Sirenas...